Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers

Journal of Pathology

Volumn 234, Issue 4, 2014, Pages 548-559

  Geurts Giele, Willemina R R ^a   Leenen, Celine H M ^b   Dubbink, Hendrikus J ^a   Meijssen, Isabelle C ^a   Post, Edward ^a   Sleddens, Hein F B M ^a   Kuipers, Ernst J ^b   Goverde, Anne ^b   Van Den Ouweland, Ans M W ^b   Van Lier, Margot G F ^b   Steyerberg, Ewout W ^b   Van Leerdam, Monique E ^b,c   Wagner, Anja ^b   Dinjens, Winand N M ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

Colorectal cancer; Germline mutation; Lynch syndrome; Mismatch repair deficiency

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SCREENING; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DNA METHYLATION; ENDOMETRIUM CANCER; FEMALE; GENE DELETION; GENE DISRUPTION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC PROCEDURES; GERMLINE MUTATION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MALE; MIDDLE AGED; MISMATCH REPAIR GENE; MLH1 GENE; MOLECULAR DIAGNOSIS; NETHERLANDS; NEXT GENERATION SEQUENCING; PROMOTER REGION; RETROSPECTIVE STUDY; SOMATIC MUTATION; TUMOR GENE; GENETICS; LYNCH SYNDROME II; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MULTIPLEX POLYMERASE CHAIN REACTION; MUTATION; NUCLEOTIDE SEQUENCE;

ADULT; AGED; DNA MISMATCH REPAIR; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; LOSS OF HETEROZYGOSITY; LYNCH SYNDROME II; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MULTIPLEX POLYMERASE CHAIN REACTION; MUTATION;

EID: 84911377223     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4419     Document Type: Article

References (42)

1. Hampel H, Frankel W, Panescu J, et al. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res 2006; 66: 7810-7817.
2. Hampel H, Frankel WL, Martin E, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 2008; 26: 5783-5788.
3. Ligtenberg MJ, Kuiper RP, Chan TL, et al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1. Nat Genet 2009; 41: 112-117.
4. Ligtenberg MJ, Kuiper RP, Geurts van Kessel A, et al. EPCAM deletion carriers constitute a unique subgroup of Lynch syndrome patients. Fam Cancer 2013; 12: 169-174.
5. Boland CR. Evolution of the nomenclature for the hereditary colorectal cancer syndromes. Fam Cancer 2005; 4: 211-218.
6. van Lier MG, Wagner A, van Leerdam ME, et al. A review on the molecular diagnostics of Lynch syndrome: a central role for the pathology laboratory. J Cell Mol Med 2010; 14: 181-197.
7. van Lier MG, Leenen CH, Wagner A, et al. Yield of routine molecular analyses in colorectal cancer patients ≤ 70 years to detect underlying Lynch syndrome. J Pathol 2012; 226: 764-774.
8. Leenen CH, van Lier MG, van Doorn HC, et al. Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer ≤ 70 years. Gynecol Oncol 2012; 125: 414-420.
9. Zhao YS, Hu FL, Wang F, et al. Meta-analysis of MSH6 gene mutation frequency in colorectal and endometrial cancers. J Toxicol Environ Health A 2009; 72: 690-697.
10. Zhang R, Qin W, Xu GL, et al. A meta-analysis of the prevalence of somatic mutations in the hMLH1 and hMSH2 genes in colorectal cancer. Colorectal Dis 2012; 14: e80-89.
11. Sourrouille I, Coulet F, Lefevre JH, et al. Somatic mosaicism and double somatic hits can lead to MSI colorectal tumors. Fam Cancer 2013; 12: 27-33.
12. Mensenkamp AR, Vogelaar IP, van Zelst-Stams WA, et al. Somatic mutations in MLH1 and MSH2 are a frequent cause of mismatch-repair deficiency in Lynch syndrome-like tumors. Gastroenterology 2014; 146: 643-646.
13. Jarvinen HJ, Aarnio M, Mustonen H, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 2000; 118: 829-834.
14. de Jong AE, Hendriks YM, Kleibeuker JH, et al. Decrease in mortality in Lynch syndrome families because of surveillance. Gastroenterology 2006; 130: 665-671.
15. Stupart DA, Goldberg PA, Algar U, et al. Surveillance colonoscopy improves survival in a cohort of subjects with a single mismatch repair gene mutation. Colorectal Dis 2009; 11: 126-130.
16. Schmeler KM, Lynch HT, Chen LM, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 2006; 354: 261-269.
17. Lurkin I, Stoehr R, Hurst CD, et al. Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes. PLoS One 2010; 5: e8802.
18. Geurts-Giele WR, Dirkx-van der Velden AW, Bartalits NM, et al. Molecular diagnostics of a single multifocal non-small cell lung cancer case using targeted next generation sequencing. Virchows Arch 2013; 462: 249-254.
19. Plon SE, Eccles DM, Easton D, et al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat 2008; 29: 1282-1291.
20. Thompson BA, Spurdle AB, Plazzer JP, et al. Application of a five-tiered scheme for standardized classification of 2360 unique mismatch repair gene variants in the InSiGHT locus-specific database. Nat Genet 2014; 46: 107-115.
21. Melcher R, Hartmann E, Zopf W, et al. LOH and copy neutral LOH (cnLOH) act as alternative mechanism in sporadic colorectal cancers with chromosomal and microsatellite instability. Carcinogenesis 2011; 32: 636-642.
22. Veigl ML, Kasturi L, Olechnowicz J, et al. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci USA 1998; 95: 8698-8702.
23. van Puijenbroek M, Middeldorp A, Tops CM, et al. Genome-wide copy neutral LOHis infrequent in familial and sporadic microsatellite unstable carcinomas. Fam Cancer 2008; 7: 319-330.
24. McGivern A, Wynter CV, Whitehall VL, et al. Promoter hypermethylation frequency and BRAF mutations distinguish hereditary non-polyposis colon cancer from sporadic MSI-H colon cancer. Fam Cancer 2004; 3: 101-107.
25. Parsons MT, Buchanan DD, Thompson B, et al. Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification. J Med Genet 2012; 49: 151-157.
26. Smalley KS, Xiao M, Villanueva J, et al. CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene 2009; 28: 85-94.
27. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11: 753-762.
28. Arcila M, Lau C, Nafa K, et al. Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping. J Mol Diagn 2011; 13: 64-73.
29. Rodriguez-Soler M, Perez-Carbonell L, Guarinos C, et al. Risk of cancer in cases of suspected Lynch syndrome without germline mutation. Gastroenterology 2013; 144: 926-932.
30. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 2010; 38: e164.
31. Giardine B, Riemer C, Hardison RC, et al. Galaxy: a platform for interactive large-scale genome analysis. Genome Res 2005; 15: 1451-1455.
32. Goecks J, Nekrutenko A, Taylor J, et al. Galaxy: a comprehensive approach for supporting accessible, reproducible, and transparent computational research in the life sciences. Genome Biol 2010; 11: R86.
33. Blankenberg D, Von Kuster G, Coraor N, et al. Galaxy: a web-based genome analysis tool for experimentalists. Curr Protoc Mol Biol 2010; 19: 19.10.11-19.10.21.
34. Tavtigian SV, Deffenbaugh AM, Yin L, et al. Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J Med Genet 2006; 43: 295-305.
35. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 2009; 4: 1073-1081.
36. Schwarz JM, Rodelsperger C, Schuelke M, et al. MutationTaster evaluates disease-causing potential of sequence alterations. Nat Methods 2010; 7: 575-576.
37. Grantham R. Amino acid difference formula to help explain protein evolution. Science 1974; 185: 862-864.
38. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Methods 2010; 7: 248-249.
39. Shihab HA, Gough J, Cooper DN, et al. Predicting the functional, molecular, and phenotypic consequences of amino acid substitutions using hidden Markov models. Hum Mutat 2013; 34: 57-65.
40. Carter H, Samayoa J, Hruban RH, et al. Prioritization of driver mutations in pancreatic cancer using cancer-specific high-throughput annotation of somatic mutations (CHASM). Cancer Biol Ther 2010; 10: 582-587.
41. Choi Y, Sims GE, Murphy S, et al. Predicting the functional effect of amino acid substitutions and indels. PLoS One 2012; 7: e46688.
42. Ellison AR, Lofing J, Bitter GA. Human MutL homolog (MLH1) function in DNA mismatch repair: a prospective screen for missense mutations in the ATPase domain. Nucleic Acids Res 2004; 32: 5321-5338.